Research Article
Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients
Table 1
Characteristics of the overall cohort and in patients with and without cardiovascular events (CVEs).
| | | Entire cohort | CVE | No CVE | | (n = 356) | (n = 63) | (n = 293) |
| | Males, n (%) | 277 (77.8) | 59 (94) | 218 (78.7) | | Age (years) at OLT, median (IQR) | 56 (49–60) | 58 (51–61) | 55 (48–60) | | Age (years) at last follow-up, median (IQR) | 64 (57–71) | 66 (62–72) | 64 (55–71) | | Etiology of liver disease | | Alcohol, n (%) | 107 (30.1) | 28 (44) | 79 (27.0) | | Viral hepatitis, n (%) | 196 (55.1) | 32 (51) | 163 (55.6) | | HCV | 149 (41.8) | 20 (31.7) | 129 (44) | | HBV | 47 (13.2) | 12 (19) | 35 (11.9) | | Nonalcoholic steatohepatitis (NASH), n (%) | 20 (5.6) | 4 (6) | 16 (5.5) | | Autoimmune/cholestatic, n (%) | 20 (5.6) | 3 (5) | 17 (5.8) | | Other, n (%) | 56 (15.7) | 3 (5) | 53 (18.1) | | Death, n (%) | 78 (21.9) | 14 (22) | 64 (22.0) | | BMI at transplant, median (IQR) | 25 (22.6–28.1) | 25.7 (23.7–29.8) | 24.7 (22.4–27.7) | | BMI at last follow-up, median (IQR) | 25.9 (23.2–28.7) | 26.6 (24.3–29.8) | 25.6 (23.0–28.4) | | Change in BMI (median, IQR) | 0.7 (1.7; 2.5) | 0.9 (2.4; 2.2) | 0.5 (1.6; 2.7) | | Diabetes pre-OLT n (%) | 93 (26.1) | 29 (46) | 64 (21.8) | | De novo diabetes n (%) | 74 (20.8) | 15 (24) | 59 (20.1) | | Arterial hypertension pre-OLT n (%) | 73 (20.5) | 17 (27) | 56 (19.1) | | De novo arterial hypertension n (%) | 143 (41.0) | 33 (52) | 110 (38.5) | | Hyperlipidemia pre-OLT n (%) | 14 (3.9) | 5 (8) | 9 (3.1) | | De novo hyperlipidemia n (%) | 153 (43.0) | 41 (65) | 112 (38.2) | | Metabolic syndrome pre-OLT n (%) | 17/322 (5.3) | 6/59 (10) | 11/263 (4.2) | | De novo metabolic syndrome n (%) | 34/322 (10.6) | 12/59 (20) | 22/263 (8.4) | | MAFLD pre-OLT n (%) | 20/256 (7.8) | 3/45 (7) | 17/211 (8.1) | | De novo MAFLD n (%) | 57/256 (22.3) | 11/45 (24) | 46/211 (21.8) |
|
|
( ) calculated for the subgroup of patients with complete information. |
